Exenatide Synthesis Quality: Evaluating Monomer Integrity via Chromatography

 

Exenatide, a 39-amino-acid synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, demands rigorous quality control throughout its manufacturing lifecycle. As a peptide therapeutic with a molecular weight of 4186.6 Da (C₁₈₄H₂₈₂N₅₀O₆₀S), its structural complexity and susceptibility to degradation necessitate sophisticated analytical strategies. Chromatography stands as the cornerstone methodology for evaluating monomer integrity, ensuring that synthesis byproducts, racemisation artefacts, and degradation products remain within pharmacopeial limits.

The Imperative for Monomer Integrity Assessment

Exenatide synthesis via solid-phase peptide synthesis (SPPS) generates a heterogeneous mixture of target peptide and process-related impurities. Critical quality attributes include D-His racemisation, which must remain below 1% according to USP criteria. The presence of D-histidine at position 1 can significantly alter receptor binding and biological activity, making its detection and quantification essential. Furthermore, the peptide's methionine residue at position 14 is susceptible to oxidation, while asparagine at position 28 can undergo succinimide formation, both compromising monomer integrity.

Chromatographic evaluation serves multiple critical functions: confirming molecular identity, quantifying purity, detecting process-related impurities, and monitoring degradation products that emerge during storage or stress conditions. The USP monograph for exenatide specifies stringent acceptance criteria, requiring 95.0% to 105.0% peptide content and strict limits on individual impurities.

Chromatographic Techniques for Monomer Integrity

Reverse-Phase HPLC

Reverse-phase high-performance liquid chromatography (RP-HPLC) represents the primary technique for exenatide purity assessment. The USP assay employs a C18 column maintained at 60°C with UV detection at 220 nm and a mobile phase gradient transitioning from ammonium hydrogen carbonate buffer to acetonitrile. This methodology effectively separates exenatide from related substances, with system suitability requiring resolution of not less than 1.0 between [Glu¹³]-exenatide and [Met(O)¹⁴]-exenatide peaks.

Modern method development increasingly leverages Analytical Quality by Design (AQbD) principles to optimise impurity profiling. Water researchers employed a systematic approach integrating risk assessment, Design of Experiments (DoE), and complementary UV and mass-based detection, ultimately identifying 19 process- and product-related impurity peaks during forced thermal degradation studies. The final method employed a CSH C18 column (130 Å, 2.5 µm, 4.6 × 150 mm) at 65°C with a 43 µL injection volume, achieving baseline resolution for critical impurity pairs.

Strong Cation Exchange Chromatography

Strong cation exchange (SCX-HPLC) is better at picking out D-His exenatide than other methods. This technique effectively separates the racemised impurity from the target peptide, with typical retention times around 21.5 minutes for D-His-exenatide. Large-scale synthesis data demonstrates that optimised processes can consistently control D-His racemisation to 0.6-1.2% as measured by SCX-HPLC, translating to 0.42-0.84% by the GC/MS reference method, remaining below the 1% USP threshold.

Liquid Chromatography-Mass Spectrometry (LC-MS)

The integration of mass spectrometry with chromatographic separation dramatically enhances monomer integrity evaluation. LC-MS workflows provide orthogonal detection, enabling identification of impurities that might be overlooked by UV detection alone. A compelling demonstration revealed that an exenatide sample exhibiting 40% spectral abundance of an impurity containing a +97.1 Da mass shift (corresponding to proline insertion) was completely missed by LC-UV analysis but readily detected through single quadrupole MS.

For degradation product characterisation, UHPLC-Orbitrap fusion mass spectrometry has proven invaluable. Force degradation studies under hydrolytic, oxidative, photolytic, and thermal stress conditions identified five major degradation products, with their fragmentation pathways elucidated through MS/MS analysis.

Evaluating Synthesis Quality Through Chromatographic Metrics

The effectiveness of exenatide synthesis is directly reflected in chromatographic purity profiles. Crude peptide obtained from SPPS typically exhibits 40-45% purity, requiring preparative chromatographic purification to meet pharmacopeial standards. Optimised purification protocols yield a final product with 98.0-99.01% purity, representing a critical quality milestone.

During cleavage from resin, scavenger selection significantly impacts impurity profiles. Research comparing scavengers, including DTT, DODT, and 1,4-benzenedimethanethiol (1,4-BDMT), demonstrated that scavenger adduct byproducts can form, with molecular weights corresponding to exenatide plus the scavenger mass minus 2 Da. EIC-MS analysis enables sensitive detection of these adducts, informing optimal cleavage conditions for monomer integrity preservation.

Conclusion

Chromatographic evaluation of exenatide monomer integrity encompasses a multi-technique strategy tailored to detect the diverse impurity classes arising from synthesis and storage. RP-HPLC provides the primary purity assessment platform, while SCX-HPLC specifically targets D-His racemisation. LC-MS integration offers orthogonal confirmation and structural characterisation of unexpected impurities and degradation products. Together, these chromatographic methodologies ensure that exenatide drug substance consistently meets the stringent quality standards required for therapeutic use, safeguarding both efficacy and patient safety.